Filing and business context
This is Wound Management Technologies, Inc. (WMT), not a filing under the name Sanara Medtech Inc., as identified in the request metadata. The Form 10-Q covers the quarter and nine months ended September 30, 2011. WMT markets CellerateRX wound-care products and describes plans to develop resorbable orthopedic products.
Financial performance and position
| Metric | Q3 2011 | Q3 2010 | Nine months 2011 | Nine months 2010 |
|---|---|---|---|---|
| Revenue | $133,841 | $111,652 | $1,296,951 | $292,609 |
| Gross profit (loss) | $(239,664) | $(184,989) | $744,293 | $(52,846) |
| Loss from continuing operations | $(751,844) | $(745,398) | $(1,811,785) | $(1,824,513) |
| Net loss | $(1,066,016) | $(1,685,279) | $(7,008,903) | $(3,594,375) |
| Basic and diluted loss per share | $(0.02) | $(0.05) | $(0.13) | $(0.10) |
Nine-month revenue includes a $500,000 non-refundable payment for Juventas’s exclusive North American distribution rights. Management attributed the revenue increase to product sales and that payment. Q3 gross margin was negative; nine-month gross margin was approximately 57%, but the upfront payment affects comparability. Nine-month G&A was $2.20 million, up 57%, which management attributed to marketing and consulting costs. Nine-month debt-related expense rose to approximately $4.09 million, largely due to equity compensation for lenders. Management said financing costs exceeded profit from increased sales.
At September 30, cash was $105,821; current assets were $1.80 million and current liabilities $2.45 million (current ratio approximately 0.73). Total assets were $7.78 million, total liabilities $2.96 million, and reported stockholders’ equity $4.81 million. The balance sheet lists $419,577 of related-party notes payable, $721,007 of notes payable net of discount, and $509,649 of debentures net of discount. Nine-month operating cash use was $583,305; investing cash use was $954,422, including net lending activity; financing provided $1.59 million. Cash increased by $54,986 from year-end.
Changes, outlook, and risks
- Nine-month net loss increased 95% year over year despite higher revenue and a narrower loss from continuing operations. Common shares issued rose from 41.3 million at year-end 2010 to 58.0 million at September 30, 2011; the company also reported 8.94 million warrants outstanding.
- The filing states substantial doubt about WMT’s ability to continue as a going concern, citing limited operations, inadequate recurring revenue, and reliance on stock and debt financing. It says additional funding and successful future operations are necessary.
- Juventas’s multiyear exclusivity is subject to escalating sales targets; the stated minimum for 2012 is $9 million. This is a contractual sales requirement, not company guidance. Management planned to file 510(k) applications for new orthopedic products in Q4 2011; no outcome is reported here.
- Financing included convertible notes with conversion prices tied to discounted market prices, warrants, and substantial stock issuance for loan fees and debt costs. These terms and ongoing financing needs create dilution and repayment risks. One June 2011 note had $61,250 past due as of the filing date; subsequent-event disclosures say $295,002 of first-quarter notes and accrued interest were paid in October.
- WMT disclosed approximately $116,642 of unpaid 2004–2005 payroll taxes and $219,406 of related penalties and interest, with a tax lien filed in 2009; settlement negotiations with the IRS were ongoing. Accrued royalties to Applied were $334,488 at quarter-end.
- Related-party transactions include loans receivable and payable and shared offices and services involving entities affiliated with the CEO. The filing reports disclosure controls were effective and no legal proceedings.
The filing contains an apparent inconsistency: Note 2 says the company has a stockholders’ deficiency, while the September 30 balance sheet reports positive stockholders’ equity of $4.81 million. Management provides no numerical forward earnings or cash-flow guidance.
Investor facts to verify
- Confirm the registrant’s identity and whether this WMT filing is the intended filing for Sanara Medtech Inc.
- Assess recurring product revenue separately from the $500,000 distribution-rights payment and evaluate CellerateRX gross margins and sales trends.
- Verify available liquidity, upcoming debt maturities, past-due amounts, financing access, and the effects of conversion discounts and warrants on dilution.
- Review the status and potential resolution of the IRS payroll-tax liability and accrued royalties.
- Reconcile the going-concern note’s statement of stockholders’ deficiency with the positive equity shown on the balance sheet.